HALO - HALOZYME THERAPEUTICS, INC.

QQQ $ 442.84 $ 1.02 (0.23 %)

DIA $ 394.52 $ -0.72 (-0.18 %)

SPY $ 520.61 $ 0.07 (0.01 %)

TLT $ 90.36 $ 0.23 (0.26 %)

GLD $ 216.28 $ -2.45 (-1.12 %)

Previous Close

$ 43.61

Open

$ 43.60

Bid

$ 0.00 x 0

Ask

$ 0.00 x 0

Day's Range

$ 43.38 - $ 43.93

52 Week Range

$ 31.86 - $ 45.00

Volume

903,477

Average Volume

Market Cap

5.62B

Beta (5Y Monthly)

$ 1.04

PE Ratio (TTM)

$ 17.63

EPS (TTM)

TBD

Earnings Date

Dividend & Yield

na ($ 0.00)

Last Ex-Dividend

1y Target Est

TBD na

How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In

#	Filing Date	Period End Date	Type
1	05-07-2024	03-31-2024	10-Q
2	02-20-2024	12-31-2023	10-K
3	11-06-2023	09-30-2023	10-Q
4	08-08-2023	06-30-2023	10-Q
5	05-09-2023	03-31-2023	10-Q
6	02-21-2023	12-31-2022	10-K
7	11-08-2022	09-30-2022	10-Q
8	08-09-2022	06-30-2022	10-Q
9	05-10-2022	03-31-2022	10-Q
10	02-22-2022	12-31-2021	10-K
11	11-02-2021	09-30-2021	10-Q
12	08-09-2021	06-30-2021	10-Q
13	05-10-2021	03-31-2021	10-Q
14	02-23-2021	12-31-2020	10-K
15	11-02-2020	09-30-2020	10-Q
16	08-10-2020	06-30-2020	10-Q
17	05-11-2020	03-31-2020	10-Q
18	02-24-2020	12-31-2019	10-K
19	11-12-2019	09-30-2019	10-Q
20	08-06-2019	06-30-2019	10-Q
21	05-07-2019	03-31-2019	10-Q
22	02-21-2019	12-31-2018	10-K
23	11-06-2018	09-30-2018	10-Q
24	08-07-2018	06-30-2018	10-Q
25	05-10-2018	03-31-2018	10-Q
26	02-20-2018	12-31-2017	10-K
27	11-07-2017	09-30-2017	10-Q
28	08-08-2017	06-30-2017	10-Q
29	05-09-2017	03-31-2017	10-Q
30	02-28-2017	12-31-2016	10-K
31	11-07-2016	09-30-2016	10-Q
32	08-09-2016	06-30-2016	10-Q
33	05-09-2016	03-31-2016	10-Q
34	02-29-2016	12-31-2015	10-K
35	11-09-2015	09-30-2015	10-Q
36	08-10-2015	06-30-2015	10-Q
37	05-11-2015	03-31-2015	10-Q
38	03-02-2015	12-31-2014	10-K
39	11-10-2014	09-30-2014	10-Q
40	08-11-2014	06-30-2014	10-Q

Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In

#	Date	Analyst Firm	Upside/Downside	Price Target Change	Rating Change	Current Rating

News
OPINIONS

News

OPINIONS

JMP Securities Maintains Market Outperform...
05/08/2024 17:58:25

JMP Securities analyst Jason Butler maintains Halozyme Therapeutics (NASDAQ:HALO) with a Market Outperform and lowers the pr...

HC Wainwright & Co. Reiterates Buy on Halo...
05/08/2024 11:30:14

HC Wainwright & Co. analyst Mitchell Kapoor reiterates Halozyme Therapeutics (NASDAQ:HALO) with a Buy and maintains $50 ...

Halozyme Reiterates FY24 Guidance: Sees To...
05/07/2024 20:29:11

Halozyme Therapeutics Q1 2024 Adj EPS $0.7...
05/07/2024 20:24:43

Halozyme Therapeutics (NASDAQ:HALO) reported quarterly earnings of $0.79 per share which beat the analyst consensus estimate of...

Expert Ratings For Halozyme Therapeutics
05/07/2024 14:00:56

HC Wainwright & Co. Reiterates Buy on Halo...
05/07/2024 10:14:31

HC Wainwright & Co. analyst Mitchell Kapoor reiterates Halozyme Therapeutics (NASDAQ:HALO) with a Buy and maintains $50 ...

HC Wainwright & Co. Reiterates Buy on Halo...
04/30/2024 10:35:58

HC Wainwright & Co. analyst Mitchell Kapoor reiterates Halozyme Therapeutics (NASDAQ:HALO) with a Buy and maintains $50 ...

HC Wainwright & Co. Reiterates Buy on Halo...
04/17/2024 15:41:14

HC Wainwright & Co. analyst Mitchell Kapoor reiterates Halozyme Therapeutics (NASDAQ:HALO) with a Buy and maintains $50 ...

9 Analysts Have This To Say About Halozyme...
04/16/2024 14:01:08

Benchmark Reiterates Buy on Halozyme Thera...
04/16/2024 13:27:28

Benchmark analyst Robert Wasserman reiterates Halozyme Therapeutics (NASDAQ:HALO) with a Buy and maintains $50 price target.

why-biophytis-shares-are-trading-higher-by-around-55-here-are-20-stocks-moving-premarket

Why Biophytis Shares Are Trading Higher By...
04/09/2024 10:05:24

Shares of Biophytis S.A. (NASDAQ: BPTS) rose sharply in today’s pre-market trading after reporting FY23 results.

TD Cowen Initiates Coverage On Halozyme Th...
02/29/2024 11:59:55

TD Cowen analyst Brendan Smith initiates coverage on Halozyme Therapeutics (NASDAQ:HALO) with a Outperform rating and announ...

JMP Securities Reiterates Market Outperfor...
02/21/2024 17:11:11

JMP Securities analyst Jason Butler reiterates Halozyme Therapeutics (NASDAQ:HALO) with a Market Outperform and maintains $7...

Breaking Down Halozyme Therapeutics: 7 Ana...
02/21/2024 12:00:45

HC Wainwright & Co. Maintains Buy on Haloz...
02/21/2024 11:45:53

HC Wainwright & Co. analyst Mitchell Kapoor maintains Halozyme Therapeutics (NASDAQ:HALO) with a Buy and raises the pric...

Halozyme Therapeutics Sees FY24 Adj. EPS $...
02/20/2024 21:40:23

Halozyme Therapeutics: Q4 Earnings Insights
02/20/2024 21:05:15

Halozyme Therapeutics Q4 Adj EPS $0.82 Mis...
02/20/2024 21:03:05

Halozyme Therapeutics (NASDAQ:HALO) reported quarterly earnings of $0.82 per share which missed the analyst consensus estimate ...

Earnings Scheduled For February 20, 2024
02/20/2024 11:52:12

Companies Reporting Before The Bell • Barclays (NYSE:BCS) is likely to report quarterly earnings at $0.36 per share on revenue...

Earnings Preview: Halozyme Therapeutics
02/19/2024 16:01:26